Mercado mundial del dolor crónico de la superficie ocular: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado del dolor crónico de la superficie ocular crezca rápidamente durante el período de pronóstico. El dolor ocular puede manifestarse de diversas formas, desde un fuerte dolor en el ojo hasta una leve molestia o picazón. Debido a que los síntomas del dolor ocular varían desde simples errores de refracción hasta trastornos potencialmente amenazantes para la vista, como el glaucoma y la uveítis, el origen de estos dolores puede ser cualquier cosa, desde simples errores de refracción hasta trastornos potencialmente amenazantes para la vista, como el glaucoma y la uveítis. Un problema en el ojo en sí mismo puede inducir una sensación de malestar o dolor en el ojo. También puede ser causado por un problema con cualquiera de las estructuras alrededor del ojo, así como por un dolor referido de tejidos que tienen una inervación similar a los tejidos oculares. Los médicos de atención primaria, neurólogos y oftalmólogos ven regularmente a pacientes con dolor ocular o dolor periorbitario.

Data Bridge Market Research analiza que el mercado del dolor crónico de la superficie ocular se valoró en USD 289 millones en 2021 y se espera que alcance los USD 450,30 millones para 2029, registrando una CAGR del 5,70% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

El dolor crónico de la superficie ocular, también conocido como oftalmología, se caracteriza por un dolor generalizado en los ojos que es persistente, intenso y opresivo. Las enfermedades médicas que inducen inflamación de la superficie ocular, como la conjuntivitis, el glaucoma y la migraña, son las causas más comunes.

Alcance del informe y segmentación del mercado

Chronic Ocular Surface Pain Market Dynamics

Drivers

• Increasing prevalence of bacterial and viral ocular infections

The rising prevalence of bacterial and viral ocular infections is estimated to enhance the market's growth.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of chronic ocular surface pain market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get chronic ocular surface pain, further estimated to enhance the market’s growth rate.

• Increasing prevalence of dry eyes among people

The rising prevalence of dry eyes among people is anticipated to propel the market's growth rate. Thyroid disorders, lupus, Sjogren’s syndrome, diabetes, rheumatoid arthritis, scleroderma, and others are the various diseases contributing to the high prevalence of dry eyes among people.    

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the chronic ocular surface pain market. Additionally, increasing demand for standard treatment and sedentary lifestyle of people will result in the expansion of chronic ocular surface pain market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the chronic ocular surface pain market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the chronic ocular surface pain market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the chronic ocular surface pain market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This chronic ocular surface pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chronic ocular surface pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Chronic ocular surface pain market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Chronic Ocular Surface Pain Market

Over the projected period, the chronic ocular surface pain market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The chronic ocular surface pain market was hampered by the supply chain slowness.

Global Chronic Ocular Surface Pain Market Scope

The chronic ocular surface pain market is segmented on the basis of drug class, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antibiotics
• Nonsteroidal Anti-Inflammatory (NSAID)
• Corticosteroids
• Others

Application

• Sinusitis
• Migraines
• Glaucoma
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Chronic Ocular Surface Pain Market Regional Analysis/Insights

The chronic ocular surface pain market is analysed and market size insights and trends are provided by country, drug class, application, end-users and distribution channel as referenced above.

The countries covered in the chronic ocular surface pain market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the chronic ocular surface pain market because of the rising prevalence of ocular diseases in this region. Additionally, rising healthcare expenditure and technological advancement in diagnostic procedure will further propel the market’s growth rate in this region.

Se espera que Asia-Pacífico crezca durante el período de pronóstico de 2022 a 2029 debido a la presencia de importantes fabricantes de medicamentos genéricos en esta región. Además, el desarrollo de la infraestructura sanitaria y el aumento de la población geriátrica impulsarán aún más la tasa de crecimiento del mercado en esta región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado del dolor crónico de la superficie ocular

El panorama competitivo del mercado del dolor crónico de la superficie ocular proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado del dolor crónico de la superficie ocular.

Algunos de los principales actores que operan en el mercado del dolor crónico de la superficie ocular son:

• F. Hoffmann-La Roche Ltd. (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suiza)
• Zydus Cadila (India)
• AstraZeneca (Reino Unido)
• Johnson & Johnson (Estados Unidos)
• Bayer AG (Alemania)
• Industrias farmacéuticas Sun Ltd. (India)
• Compañía Bristol-Myers Squibb (Estados Unidos)
• Eli Lilly and Company (Estados Unidos)
• LEO Pharma A/S (Dinamarca)
• Glenmark Pharmaceuticals Limited (India)
• Aurobindo Pharma (India)
• Lupino (India)
• Reata Pharmaceuticals, Inc (EE. UU.)
• Kala Pharmaceuticals, Inc. (Estados Unidos)

SKU-54025